Focused On-demand Library for N-acetyltransferase ESCO2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q56NI9

UPID:

ESCO2_HUMAN

Alternative names:

Establishment factor-like protein 2; Establishment of cohesion 1 homolog 2

Alternative UPACC:

Q56NI9; B3KW59; Q49AP4

Background:

N-acetyltransferase ESCO2, also known as Establishment factor-like protein 2, plays a crucial role in sister chromatid cohesion. This protein ensures that only sister chromatids are paired together by acetylating the cohesin component SMC3, a process vital for DNA replication and cell division.

Therapeutic significance:

Mutations in ESCO2 are linked to Roberts-SC phocomelia syndrome and Juberg-Hayward syndrome, disorders characterized by limb and facial abnormalities. Understanding the role of N-acetyltransferase ESCO2 could open doors to potential therapeutic strategies for these genetic conditions.